IPP Bureau
Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
By IPP Bureau - November 07, 2024
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
By IPP Bureau - November 07, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
By IPP Bureau - November 07, 2024
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
By IPP Bureau - November 07, 2024
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
By IPP Bureau - November 06, 2024
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
By IPP Bureau - November 06, 2024
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
By IPP Bureau - November 06, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
By IPP Bureau - November 06, 2024
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
By IPP Bureau - November 06, 2024
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
By IPP Bureau - November 05, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Imtiyaz Basade appointed Senior VP of NATCO Pharma
By IPP Bureau - November 05, 2024
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
By IPP Bureau - November 05, 2024
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics
By IPP Bureau - November 05, 2024
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Emcure Pharma forms subsidiary to strengthen dermatology portfolio
By IPP Bureau - November 04, 2024
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
By IPP Bureau - November 04, 2024
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
